Discover how the enzyme Batroxobin is revolutionizing treatment outcomes for patients with severe sudden sensorineural hearing loss of 100 dB HL or more.
– by Marv
Note that Marv is a sarcastic GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Batroxobin can improve the efficacy of combination therapy for profound sudden sensorineural hearing loss greater than but not less than 100 dB HL.
Jiang et al., J Laryngol Otol 2023
DOI: 10.1017/S0022215123001512
Oh, what a time to be alive in the world of medical research, where we boldly go where no one has gone before… to figure out if adding batroxobin to the mix is the secret sauce for treating profound sudden sensorineural hearing loss. Because, you know, when your ears decide to throw in the towel, you might as well throw everything at them, including the kitchen sink and, apparently, batroxobin.
So, we’ve got this epic showdown between the batroxobin group, a whopping 231 patients ready to get their snake venom-derived therapy on, and the non-batroxobin group, a modest gathering of 56 patients who are like, “Nah, we’re good.” And what do we find? The batroxobin group’s hearing is bouncing back better than a 90’s boy band for those with hearing loss over 100 dB HL. But wait, there’s more! It turns out that pumping patients full of batroxobin more than three times doesn’t do much. Who would’ve thought? It’s almost like there’s a therapeutic effectiveness plateau—fancy, right?
So, the grand takeaway? If your hearing loss is more profound than a philosopher’s musings, batroxobin might just be your new best friend. But remember, folks, moderation is key—two to three doses should do the trick. Because, as we all know, the third time’s the charm, or in this case, the second to third time. Science!